| United Press International, Sept.
7 2006
A combination statin therapy that lowers bad cholesterol can
also reduce life-threatening inflammation linked to heart disease,
say U.S. researchers.
Study leader Dr. Christie Ballantyne, cardiologist at the Methodist
DeBakey Heart Center in Houston, says the study shows a 46-percent
reduction in C-reactive protein, or CRP, a marker for inflammation,
in patients treated with 40 mg of rosuvastatin and 10 mg ezetimibe
-- a statin therapy that has shown to lower bad cholesterol by
70 percent.
"Inflammation can lead to serious complications such as
heart attack and stroke, and high levels of CRP can predict these
risks years before they actually occur," said Ballantyne.
"Physicians have long relied on blood cholesterol as a key
indicator of cardiovascular risk, but recent research suggests
that high risk patients who achieved a low CRP level combined
with a low LDL-c (bad cholesterol) level had the fewest cardiovascular
events."
The study of 465 patients in five different countries found that
after six weeks of the combination statin therapy 58 percent of
patients achieved dual goals of lowering CRP and LDL-c.
The findings will be presented this week at the World Congress
of Cardiology in Barcelona, Spain.
|